HT
TVTX icon

HAP Trading’s Travere Therapeutics TVTX Stock Holding History

HAP Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,900
Closed -$9K – 2860
2021
Q3 		$9K Buy
16,900
+1,600
+10% +$29.4K ﹤0.01% 2047
2021
Q2 		$15K Buy
+15,300
New +$302K ﹤0.01% 1900
2021
Q1 		– Sell
-15,100
Closed -$20K – 2419
2020
Q4 		$20K Buy
+15,100
New +$353K ﹤0.01% 1706
2016
Q2 		– Sell
-58,900
Closed -$80K – 1044
2016
Q1 		$80K Buy
+58,900
New +$894K 0.01% 482
2015
Q4 		– Sell
-15,000
Closed -$110K – 1114
2015
Q3 		$110K Buy
+15,000
New +$444K 0.01% 596

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HAP Trading's TVTX Position: Q2 2017 in Review

HAP Trading sold out of Travere Therapeutics (TVTX) in Q2 2017, closing a stake of 52,767 shares — an estimated $974K sold.

HAP Trading first reported a position in TVTX in Q1 2017 and held it in 1 quarter. The position peaked at $974K in Q1 2017. 108 funds tracked by Wall St. Rank hold TVTX as of Q2 2017.

  • HAP Trading reported no remaining Travere Therapeutics position as of Q2 2017 after selling out during the quarter.
  • HAP Trading sold 52,767 Travere Therapeutics shares in Q2 2017, an estimated $974K.
  • HAP Trading first reported a position in Travere Therapeutics in Q1 2017 and held it in 1 quarter.
  • HAP Trading's Travere Therapeutics position peaked at $974K in Q1 2017.
  • 108 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2017.

Based on HAP Trading's 13F filing for Q2 2017, filed 10 Aug 2017.